Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation: A SAKURA AF Registry substudy
•Of 3237 patients, 200 (6.2%) died during a median 39.3 months follow-up period.•Patients succumbed mainly to cardiac death, malignancy, or respiratory infection.•The major determinants of vascular and nonvascular deaths differed slightly. The incidence and causes of death among patients in Japan tr...
Gespeichert in:
| Veröffentlicht in: | Journal of cardiology 2019-03, Vol.73 (3), p.210-217 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 217 |
|---|---|
| container_issue | 3 |
| container_start_page | 210 |
| container_title | Journal of cardiology |
| container_volume | 73 |
| creator | Kuronuma, Keiichiro Okumura, Yasuo Yokoyama, Katsuaki Matsumoto, Naoya Tachibana, Eizo Oiwa, Koji Matsumoto, Michiaki Kojima, Toshiaki Hanada, Shoji Nomoto, Kazumiki Arima, Ken Takahashi, Fumiyuki Kotani, Tomobumi Ikeya, Yukitoshi Fukushima, Seiji Itou, Satoru Kondo, Kunio Chiku, Masaaki Ohno, Yasumi Onikura, Motoyuki Hirayama, Atsushi |
| description | •Of 3237 patients, 200 (6.2%) died during a median 39.3 months follow-up period.•Patients succumbed mainly to cardiac death, malignancy, or respiratory infection.•The major determinants of vascular and nonvascular deaths differed slightly.
The incidence and causes of death among patients in Japan treated for atrial fibrillation (AF), a major determinant of strokes and death, with direct oral anticoagulants (DOACs) are unclear. This study's aim was two-fold: to compare the incidence and causes of death between DOAC and warfarin users in Japan and to identify the factors associated with vascular and nonvascular death in the Japanese AF population.
The study was based on the SAKURA AF registry, in which clinical events were tracked in 3267 enrollees from 63 institutions for 2–4 years. Enrollees included warfarin users (n=1577) and users of any of 4 DOACs (n=1690). The incidence, cause, and major determinants of death were analyzed.
During a median 39.3-month follow-up, 200 patients died, with most succumbing to cardiac death (25%), malignancies (21%), or respiratory infections (20%). There was no significant difference in deaths from any cause between warfarin and DOAC users (108 vs. 92 patients, p=0.34). An age ≥75 years was found to be a major determinant of death, but the relative risk (vs. |
| doi_str_mv | 10.1016/j.jjcc.2018.12.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2161698525</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0914508718303332</els_id><sourcerecordid>2161698525</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-add36dd2f0ccb2c59439951ce779d8f22ea723a1ed13d0375180db46bc76aedf3</originalsourceid><addsrcrecordid>eNp9kE1P3DAQhi1EVRboH-CAfOSS4I_ESRCXCEqLioTEx9ly7DE4yjqL7YD20P9OVgscOY1G88yrmQehI0pySqg47fO-1zpnhNY5ZTkhfActaF2JrKh4vYsWpKFFVpK62kP7MfaECNLU4ifa46RsKGd8gf5fOmshgE_YQIKwdF75FPFo8auKehpUwMob7Ef_1RtQ6Tli5_FKJQcb_M2lZ6xScGrA1nXBDcM8Gv0ZbvF9--_xrsXtFb6DJxdTWOM4dTFNZn2Iflg1RPj1UQ_Q49Xvh4u_2c3tn-uL9ibTBStSpozhwhhmidYd02VT8KYpqYaqakxtGQNVMa4oGMoN4VVJa2K6QnS6EgqM5QfoZJu7CuPLBDHJpYsa5iM9jFOUjAoqmrpk5YyyLarDGGMAK1fBLVVYS0rkRrvs5Ua73GiXlMlZ-7x0_JE_dUswXyufnmfgfAvA_OWrgyCjns1pMC6ATtKM7rv8d7nzlb0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2161698525</pqid></control><display><type>article</type><title>Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation: A SAKURA AF Registry substudy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kuronuma, Keiichiro ; Okumura, Yasuo ; Yokoyama, Katsuaki ; Matsumoto, Naoya ; Tachibana, Eizo ; Oiwa, Koji ; Matsumoto, Michiaki ; Kojima, Toshiaki ; Hanada, Shoji ; Nomoto, Kazumiki ; Arima, Ken ; Takahashi, Fumiyuki ; Kotani, Tomobumi ; Ikeya, Yukitoshi ; Fukushima, Seiji ; Itou, Satoru ; Kondo, Kunio ; Chiku, Masaaki ; Ohno, Yasumi ; Onikura, Motoyuki ; Hirayama, Atsushi</creator><creatorcontrib>Kuronuma, Keiichiro ; Okumura, Yasuo ; Yokoyama, Katsuaki ; Matsumoto, Naoya ; Tachibana, Eizo ; Oiwa, Koji ; Matsumoto, Michiaki ; Kojima, Toshiaki ; Hanada, Shoji ; Nomoto, Kazumiki ; Arima, Ken ; Takahashi, Fumiyuki ; Kotani, Tomobumi ; Ikeya, Yukitoshi ; Fukushima, Seiji ; Itou, Satoru ; Kondo, Kunio ; Chiku, Masaaki ; Ohno, Yasumi ; Onikura, Motoyuki ; Hirayama, Atsushi ; for the SAKURA AF Registry Investigators ; SAKURA AF Registry Investigators</creatorcontrib><description>•Of 3237 patients, 200 (6.2%) died during a median 39.3 months follow-up period.•Patients succumbed mainly to cardiac death, malignancy, or respiratory infection.•The major determinants of vascular and nonvascular deaths differed slightly.
The incidence and causes of death among patients in Japan treated for atrial fibrillation (AF), a major determinant of strokes and death, with direct oral anticoagulants (DOACs) are unclear. This study's aim was two-fold: to compare the incidence and causes of death between DOAC and warfarin users in Japan and to identify the factors associated with vascular and nonvascular death in the Japanese AF population.
The study was based on the SAKURA AF registry, in which clinical events were tracked in 3267 enrollees from 63 institutions for 2–4 years. Enrollees included warfarin users (n=1577) and users of any of 4 DOACs (n=1690). The incidence, cause, and major determinants of death were analyzed.
During a median 39.3-month follow-up, 200 patients died, with most succumbing to cardiac death (25%), malignancies (21%), or respiratory infections (20%). There was no significant difference in deaths from any cause between warfarin and DOAC users (108 vs. 92 patients, p=0.34). An age ≥75 years was found to be a major determinant of death, but the relative risk (vs. <75 years) was greater for nonvascular death (hazard ratio: 2.85 and 4.97 for age 75–84 and ≥85 years, respectively) than vascular death (2.14 and 2.98 for 75–84 and ≥85 years, respectively). Heart failure, renal dysfunction, and the type of institution were major determinants of vascular death, and a male sex, weight <50kg, and anemia were major determinants of nonvascular death.
The results of our AF registry-based study, in which two thirds of the enrolled patients succumbed to cardiac death, malignancies, or respiratory infections within 2– 4 years and use of DOACs rather than warfarin did not reduce the mortality, indicated that a management of AF that includes prophylaxis for vascular and nonvascular events in addition to strokes is warranted.</description><identifier>ISSN: 0914-5087</identifier><identifier>EISSN: 1876-4738</identifier><identifier>DOI: 10.1016/j.jjcc.2018.12.003</identifier><identifier>PMID: 30591323</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants - administration & dosage ; Atrial fibrillation ; Atrial Fibrillation - complications ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - mortality ; Cause of Death ; Direct oral anticoagulant ; Female ; Humans ; Incidence ; Japan - epidemiology ; Male ; Middle Aged ; Proportional Hazards Models ; Registries ; Risk Factors ; Stroke - etiology ; Stroke - mortality ; Stroke - prevention & control ; Time Factors ; Treatment Outcome ; Warfarin ; Warfarin - administration & dosage</subject><ispartof>Journal of cardiology, 2019-03, Vol.73 (3), p.210-217</ispartof><rights>2018 Japanese College of Cardiology</rights><rights>Copyright © 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-add36dd2f0ccb2c59439951ce779d8f22ea723a1ed13d0375180db46bc76aedf3</citedby><cites>FETCH-LOGICAL-c424t-add36dd2f0ccb2c59439951ce779d8f22ea723a1ed13d0375180db46bc76aedf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0914508718303332$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30591323$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuronuma, Keiichiro</creatorcontrib><creatorcontrib>Okumura, Yasuo</creatorcontrib><creatorcontrib>Yokoyama, Katsuaki</creatorcontrib><creatorcontrib>Matsumoto, Naoya</creatorcontrib><creatorcontrib>Tachibana, Eizo</creatorcontrib><creatorcontrib>Oiwa, Koji</creatorcontrib><creatorcontrib>Matsumoto, Michiaki</creatorcontrib><creatorcontrib>Kojima, Toshiaki</creatorcontrib><creatorcontrib>Hanada, Shoji</creatorcontrib><creatorcontrib>Nomoto, Kazumiki</creatorcontrib><creatorcontrib>Arima, Ken</creatorcontrib><creatorcontrib>Takahashi, Fumiyuki</creatorcontrib><creatorcontrib>Kotani, Tomobumi</creatorcontrib><creatorcontrib>Ikeya, Yukitoshi</creatorcontrib><creatorcontrib>Fukushima, Seiji</creatorcontrib><creatorcontrib>Itou, Satoru</creatorcontrib><creatorcontrib>Kondo, Kunio</creatorcontrib><creatorcontrib>Chiku, Masaaki</creatorcontrib><creatorcontrib>Ohno, Yasumi</creatorcontrib><creatorcontrib>Onikura, Motoyuki</creatorcontrib><creatorcontrib>Hirayama, Atsushi</creatorcontrib><creatorcontrib>for the SAKURA AF Registry Investigators</creatorcontrib><creatorcontrib>SAKURA AF Registry Investigators</creatorcontrib><title>Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation: A SAKURA AF Registry substudy</title><title>Journal of cardiology</title><addtitle>J Cardiol</addtitle><description>•Of 3237 patients, 200 (6.2%) died during a median 39.3 months follow-up period.•Patients succumbed mainly to cardiac death, malignancy, or respiratory infection.•The major determinants of vascular and nonvascular deaths differed slightly.
The incidence and causes of death among patients in Japan treated for atrial fibrillation (AF), a major determinant of strokes and death, with direct oral anticoagulants (DOACs) are unclear. This study's aim was two-fold: to compare the incidence and causes of death between DOAC and warfarin users in Japan and to identify the factors associated with vascular and nonvascular death in the Japanese AF population.
The study was based on the SAKURA AF registry, in which clinical events were tracked in 3267 enrollees from 63 institutions for 2–4 years. Enrollees included warfarin users (n=1577) and users of any of 4 DOACs (n=1690). The incidence, cause, and major determinants of death were analyzed.
During a median 39.3-month follow-up, 200 patients died, with most succumbing to cardiac death (25%), malignancies (21%), or respiratory infections (20%). There was no significant difference in deaths from any cause between warfarin and DOAC users (108 vs. 92 patients, p=0.34). An age ≥75 years was found to be a major determinant of death, but the relative risk (vs. <75 years) was greater for nonvascular death (hazard ratio: 2.85 and 4.97 for age 75–84 and ≥85 years, respectively) than vascular death (2.14 and 2.98 for 75–84 and ≥85 years, respectively). Heart failure, renal dysfunction, and the type of institution were major determinants of vascular death, and a male sex, weight <50kg, and anemia were major determinants of nonvascular death.
The results of our AF registry-based study, in which two thirds of the enrolled patients succumbed to cardiac death, malignancies, or respiratory infections within 2– 4 years and use of DOACs rather than warfarin did not reduce the mortality, indicated that a management of AF that includes prophylaxis for vascular and nonvascular events in addition to strokes is warranted.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants - administration & dosage</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - complications</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Fibrillation - mortality</subject><subject>Cause of Death</subject><subject>Direct oral anticoagulant</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Japan - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Proportional Hazards Models</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>Stroke - etiology</subject><subject>Stroke - mortality</subject><subject>Stroke - prevention & control</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Warfarin</subject><subject>Warfarin - administration & dosage</subject><issn>0914-5087</issn><issn>1876-4738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1P3DAQhi1EVRboH-CAfOSS4I_ESRCXCEqLioTEx9ly7DE4yjqL7YD20P9OVgscOY1G88yrmQehI0pySqg47fO-1zpnhNY5ZTkhfActaF2JrKh4vYsWpKFFVpK62kP7MfaECNLU4ifa46RsKGd8gf5fOmshgE_YQIKwdF75FPFo8auKehpUwMob7Ef_1RtQ6Tli5_FKJQcb_M2lZ6xScGrA1nXBDcM8Gv0ZbvF9--_xrsXtFb6DJxdTWOM4dTFNZn2Iflg1RPj1UQ_Q49Xvh4u_2c3tn-uL9ibTBStSpozhwhhmidYd02VT8KYpqYaqakxtGQNVMa4oGMoN4VVJa2K6QnS6EgqM5QfoZJu7CuPLBDHJpYsa5iM9jFOUjAoqmrpk5YyyLarDGGMAK1fBLVVYS0rkRrvs5Ua73GiXlMlZ-7x0_JE_dUswXyufnmfgfAvA_OWrgyCjns1pMC6ATtKM7rv8d7nzlb0</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Kuronuma, Keiichiro</creator><creator>Okumura, Yasuo</creator><creator>Yokoyama, Katsuaki</creator><creator>Matsumoto, Naoya</creator><creator>Tachibana, Eizo</creator><creator>Oiwa, Koji</creator><creator>Matsumoto, Michiaki</creator><creator>Kojima, Toshiaki</creator><creator>Hanada, Shoji</creator><creator>Nomoto, Kazumiki</creator><creator>Arima, Ken</creator><creator>Takahashi, Fumiyuki</creator><creator>Kotani, Tomobumi</creator><creator>Ikeya, Yukitoshi</creator><creator>Fukushima, Seiji</creator><creator>Itou, Satoru</creator><creator>Kondo, Kunio</creator><creator>Chiku, Masaaki</creator><creator>Ohno, Yasumi</creator><creator>Onikura, Motoyuki</creator><creator>Hirayama, Atsushi</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190301</creationdate><title>Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation: A SAKURA AF Registry substudy</title><author>Kuronuma, Keiichiro ; Okumura, Yasuo ; Yokoyama, Katsuaki ; Matsumoto, Naoya ; Tachibana, Eizo ; Oiwa, Koji ; Matsumoto, Michiaki ; Kojima, Toshiaki ; Hanada, Shoji ; Nomoto, Kazumiki ; Arima, Ken ; Takahashi, Fumiyuki ; Kotani, Tomobumi ; Ikeya, Yukitoshi ; Fukushima, Seiji ; Itou, Satoru ; Kondo, Kunio ; Chiku, Masaaki ; Ohno, Yasumi ; Onikura, Motoyuki ; Hirayama, Atsushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-add36dd2f0ccb2c59439951ce779d8f22ea723a1ed13d0375180db46bc76aedf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants - administration & dosage</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - complications</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Fibrillation - mortality</topic><topic>Cause of Death</topic><topic>Direct oral anticoagulant</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Japan - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Proportional Hazards Models</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>Stroke - etiology</topic><topic>Stroke - mortality</topic><topic>Stroke - prevention & control</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Warfarin</topic><topic>Warfarin - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuronuma, Keiichiro</creatorcontrib><creatorcontrib>Okumura, Yasuo</creatorcontrib><creatorcontrib>Yokoyama, Katsuaki</creatorcontrib><creatorcontrib>Matsumoto, Naoya</creatorcontrib><creatorcontrib>Tachibana, Eizo</creatorcontrib><creatorcontrib>Oiwa, Koji</creatorcontrib><creatorcontrib>Matsumoto, Michiaki</creatorcontrib><creatorcontrib>Kojima, Toshiaki</creatorcontrib><creatorcontrib>Hanada, Shoji</creatorcontrib><creatorcontrib>Nomoto, Kazumiki</creatorcontrib><creatorcontrib>Arima, Ken</creatorcontrib><creatorcontrib>Takahashi, Fumiyuki</creatorcontrib><creatorcontrib>Kotani, Tomobumi</creatorcontrib><creatorcontrib>Ikeya, Yukitoshi</creatorcontrib><creatorcontrib>Fukushima, Seiji</creatorcontrib><creatorcontrib>Itou, Satoru</creatorcontrib><creatorcontrib>Kondo, Kunio</creatorcontrib><creatorcontrib>Chiku, Masaaki</creatorcontrib><creatorcontrib>Ohno, Yasumi</creatorcontrib><creatorcontrib>Onikura, Motoyuki</creatorcontrib><creatorcontrib>Hirayama, Atsushi</creatorcontrib><creatorcontrib>for the SAKURA AF Registry Investigators</creatorcontrib><creatorcontrib>SAKURA AF Registry Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuronuma, Keiichiro</au><au>Okumura, Yasuo</au><au>Yokoyama, Katsuaki</au><au>Matsumoto, Naoya</au><au>Tachibana, Eizo</au><au>Oiwa, Koji</au><au>Matsumoto, Michiaki</au><au>Kojima, Toshiaki</au><au>Hanada, Shoji</au><au>Nomoto, Kazumiki</au><au>Arima, Ken</au><au>Takahashi, Fumiyuki</au><au>Kotani, Tomobumi</au><au>Ikeya, Yukitoshi</au><au>Fukushima, Seiji</au><au>Itou, Satoru</au><au>Kondo, Kunio</au><au>Chiku, Masaaki</au><au>Ohno, Yasumi</au><au>Onikura, Motoyuki</au><au>Hirayama, Atsushi</au><aucorp>for the SAKURA AF Registry Investigators</aucorp><aucorp>SAKURA AF Registry Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation: A SAKURA AF Registry substudy</atitle><jtitle>Journal of cardiology</jtitle><addtitle>J Cardiol</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>73</volume><issue>3</issue><spage>210</spage><epage>217</epage><pages>210-217</pages><issn>0914-5087</issn><eissn>1876-4738</eissn><abstract>•Of 3237 patients, 200 (6.2%) died during a median 39.3 months follow-up period.•Patients succumbed mainly to cardiac death, malignancy, or respiratory infection.•The major determinants of vascular and nonvascular deaths differed slightly.
The incidence and causes of death among patients in Japan treated for atrial fibrillation (AF), a major determinant of strokes and death, with direct oral anticoagulants (DOACs) are unclear. This study's aim was two-fold: to compare the incidence and causes of death between DOAC and warfarin users in Japan and to identify the factors associated with vascular and nonvascular death in the Japanese AF population.
The study was based on the SAKURA AF registry, in which clinical events were tracked in 3267 enrollees from 63 institutions for 2–4 years. Enrollees included warfarin users (n=1577) and users of any of 4 DOACs (n=1690). The incidence, cause, and major determinants of death were analyzed.
During a median 39.3-month follow-up, 200 patients died, with most succumbing to cardiac death (25%), malignancies (21%), or respiratory infections (20%). There was no significant difference in deaths from any cause between warfarin and DOAC users (108 vs. 92 patients, p=0.34). An age ≥75 years was found to be a major determinant of death, but the relative risk (vs. <75 years) was greater for nonvascular death (hazard ratio: 2.85 and 4.97 for age 75–84 and ≥85 years, respectively) than vascular death (2.14 and 2.98 for 75–84 and ≥85 years, respectively). Heart failure, renal dysfunction, and the type of institution were major determinants of vascular death, and a male sex, weight <50kg, and anemia were major determinants of nonvascular death.
The results of our AF registry-based study, in which two thirds of the enrolled patients succumbed to cardiac death, malignancies, or respiratory infections within 2– 4 years and use of DOACs rather than warfarin did not reduce the mortality, indicated that a management of AF that includes prophylaxis for vascular and nonvascular events in addition to strokes is warranted.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30591323</pmid><doi>10.1016/j.jjcc.2018.12.003</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-5087 |
| ispartof | Journal of cardiology, 2019-03, Vol.73 (3), p.210-217 |
| issn | 0914-5087 1876-4738 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2161698525 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Administration, Oral Aged Aged, 80 and over Anticoagulants - administration & dosage Atrial fibrillation Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Atrial Fibrillation - mortality Cause of Death Direct oral anticoagulant Female Humans Incidence Japan - epidemiology Male Middle Aged Proportional Hazards Models Registries Risk Factors Stroke - etiology Stroke - mortality Stroke - prevention & control Time Factors Treatment Outcome Warfarin Warfarin - administration & dosage |
| title | Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation: A SAKURA AF Registry substudy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T20%3A41%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Different%20determinants%20of%20vascular%20and%20nonvascular%20deaths%20in%20patients%20with%20atrial%20fibrillation:%20A%20SAKURA%20AF%20Registry%20substudy&rft.jtitle=Journal%20of%20cardiology&rft.au=Kuronuma,%20Keiichiro&rft.aucorp=for%20the%20SAKURA%20AF%20Registry%20Investigators&rft.date=2019-03-01&rft.volume=73&rft.issue=3&rft.spage=210&rft.epage=217&rft.pages=210-217&rft.issn=0914-5087&rft.eissn=1876-4738&rft_id=info:doi/10.1016/j.jjcc.2018.12.003&rft_dat=%3Cproquest_cross%3E2161698525%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2161698525&rft_id=info:pmid/30591323&rft_els_id=S0914508718303332&rfr_iscdi=true |